Multiple Myeloma Research Foundation (MMRF) Names Millennium Collaborator of
CAMBRIDGE, Mass. -- January 23, 2013
Millennium: The Takeda Oncology Company today announced that the Multiple
Myeloma Research Foundation (MMRF) has named Millennium as the first recipient
of the MMRF Collaborator Award. The award recognizes Millennium for its
outstanding commitment to collaboration to advance the research and
development of more effective treatments for multiple myeloma.
“It’s a terrific honor for Millennium to receive the first-ever Collaborator
Award from the MMRF,” said Deborah Dunsire, M.D., President and Chief
Executive Officer of Millennium. “We are very proud to be partners with the
MMRF and extend our gratitude for this award and for the MMRF’s commitment to
patients with multiple myeloma.”
“Millennium has demonstrated extraordinary vision and a dedication to
transforming multiple myeloma research and drug development to improve
outcomes for patients,” said Kathy Giusti, Founder and CEO of the MMRF and a
multiple myeloma patient. “In particular, Millennium’s early and enthusiastic
support of the MMRF CoMMpass study ensured that this landmark study lost no
momentum in opening.”
Additional awards announced by the MMRF included Washington University in St.
Louis, which received the MMRF Innovator Award, and a team of researchers from
the Dana-Farber Cancer Institute, who received the MMRF Accelerator Award.
MMRF Collaborator Award
The MMRF Collaborator Award recognizes Millennium: The Takeda Oncology Company
for its outstanding commitment to collaboration as a means to advance the
research and development of more effective treatments for patients with
multiple myeloma. The company has also partnered with the MMRC to launch
highly innovative clinical trials through the Multiple Myeloma Research
Consortium - four trials in 2012 alone and 22 trials overall.
About the Multiple Myeloma Research Foundation (MMRF)
The Multiple Myeloma Research Foundation (MMRF) was established in 1998 as a
501(c)(3) non-profit organization by twin sisters Karen Andrews and Kathy
Giusti, soon after Kathy's diagnosis with multiple myeloma. The mission of the
MMRF is to relentlessly pursue innovative means that accelerate the
development of next-generation multiple myeloma treatments to extend the lives
of patients and lead to a cure. As the world's number-one private funder of
multiple myeloma research, the MMRF has raised over $200 million since its
inception and directs 90% of total budget to research and related programming.
As a result, the MMRF has been awarded Charity Navigator’s coveted four
four-star rating for nine consecutive years, the highest designation for
outstanding fiscal responsibility and exceptional efficiency. For more
information about the MMRF, visit www.themmrf.org.
Millennium: The Takeda Oncology Company, a leading biopharmaceutical company
based in Cambridge, Mass., markets VELCADE, a first-in-class proteasome
inhibitor, and has a robust clinical development pipeline of product
candidates. Millennium Pharmaceuticals, Inc. was acquired by Takeda
Pharmaceutical Company Ltd. in May, 2008. The Company’s research, development
and commercialization activities are focused in oncology. Additional
information about Millennium is available through its website,
Editors’ Note: This press release is also available under the Media section of
the Company’s website at: www.millennium.com/InTheNews.aspx.
For Millennium: The Takeda Oncology Company
Manisha Pai, 617-551-7877
David Albaugh, 617-444-4457
Press spacebar to pause and continue. Press esc to stop.